查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2023506

流感疫苗市場分析及預測（至2035年）：類型、產品、技術、適應性、劑型、通路、給藥途徑

Influenza Vaccine Market Analysis and Forecast to 2035: Type, Product, Technology, Application, Mode, Distribution Channel, Route of Administration
出版日期: | 出版商: Global Insight Services | 英文 350 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

全球流感疫苗市場預計將從2025年的92億美元成長到2035年的163億美元，複合年成長率（CAGR）為5.7%。全球系統化的指南和強勁的季節性需求趨勢是推動流感疫苗市場成長的主要因素。世界衛生組織（WHO）確保了可預測的生產週期，而美國疾病管制與預防中心（CDC）報告稱，在2025-2026流感季，美國共分發了1.346億劑疫苗。歐洲疾病預防控制中心（ECDC）的數據顯示，多個國家的疫苗有效率已達到約50%，歐洲住院率下降26%至41%也為公共資金支持提供了支持。全球疫苗產能已達15.3億劑，但區域差異仍存在，疫苗接種率從少於15%到超過75%不等。

在全球流感疫苗市場中，產品可分為去活化疫苗、減毒活病毒疫苗和重組疫苗。去活化疫苗憑藉其良好的安全性、廣泛的監管核准以及在國家免疫規劃中的廣泛應用，在該領域佔據主導地位，預計到2025年市場規模將達到約80.12億美元。這些疫苗是群體接種和高風險族群接種的首選。另一方面，減毒活疫苗因其無需注射且能刺激黏膜免疫而備受關注。重組疫苗也因其快速、無蛋生產流程和強大的免疫反應而擴大市場，支持創新並提高對全球不斷演變的流感病毒株的保護能力。

市場區隔
類型 四價疫苗、三價疫苗
產品 活病毒疫苗、重組疫苗、不活化疫苗
科技 卵源性、重組DNA、細胞源性
適應 兒童、青年人、老人、孕婦
劑型 肌肉注射、鼻內注射、皮內注射
分銷管道 醫院和藥房、政府和機構供應商以及其他
給藥途徑 鼻腔注射

在全球流感疫苗市場中，科技主要分為雞蛋來源、細胞來源、重組DNA平台三大類。雞蛋來源技術憑藉其長期穩定的生產基礎設施和大規模生產能力，仍佔據主導地位，預計到2025年市場規模將達到約67.132億美元。然而，由於細胞來源疫苗在生產過程中具有更高的有效性和更低的突變風險，其應用日益廣泛。重組DNA技術也因其高精度和不受雞蛋供應限制而備受關注。毒株選擇的不斷更新以及對更有效疫苗日益成長的需求，正在推動所有技術的創新，製造商們正致力於提高生產效率和疫苗性能。

區域概覽

到2025年，北美將引領全球流感疫苗市場，約佔總銷售額的47.6%。這一成長主要得益於美國和加拿大強力的免疫接種計劃以及持續的監管進展。疫苗接種率的上升得益於核准範圍的擴大，包括更廣泛年齡層的接種以及疫苗供應的改善。強調年度接種和早期分發策略的公共衛生措施進一步推動了疫苗需求。此外，人們對流感相關住院和死亡的認知不斷提高，也促進了疫苗的持續接種，並鞏固了北美在全球市場的主導地位。

亞太地區預計將成為全球成長最快的流感疫苗市場，2026年至2035年的複合年成長率將達到9.6%。這一成長主要得益於中國、印度、日本和韓國免疫接種指南的擴展以及疾病負擔的加重。這些國家的政府正在大力推動免疫宣傳活動，更新疫苗株組成，並提高疫苗接種率，並覆蓋更廣泛的人口。四價疫苗的普及和公共衛生宣傳活動的加強，提高了公眾的認知度和疫苗可及性，使亞太地區成為全球流感疫苗市場的高成長區域。

主要趨勢和促進因素

流感疫苗市場中先進數位化疫苗接種解決方案的興起：

在mRNA技術、人工智慧預測和個人化免疫策略等創新技術的推動下，流感疫苗市場正朝著先進的、數位整合的疫苗接種解決方案轉型。 Moderna、賽諾菲巴斯德和輝瑞等公司正大力推動四價疫苗、數位追蹤平台和人工智慧驅動的研發。此外，Seqirus和葛蘭素史克等公司正在利用預測分析和個人化方案來最佳化供應鏈和最終效果。這些趨勢凸顯了疫苗接種生態系統正朝著精準驅動、互聯且高效的方向發展。

加速流感疫苗市場創新流感疫苗的研發與供應：

流感疫苗市場的發展主要得益於疫苗研發、數位化監測和供應鏈最佳化的快速進展。輝瑞和Astra Zeneca等公司正在拓展mRNA平台和即時監測工具，以提高應對疫情的準備程度和疫苗接種率。同時，Cekilus和賽諾菲巴斯德等公司正透過佐劑聯合疫苗和可擴展包裝來增強免疫反應和物流系統。與GlaxoSmithKline Plc的合作進一步提升了感染疾病預測管理能力。這些因素共同作用，提高了全球免疫系統的效率、可近性和韌性。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 四價疫苗
    • 三價疫苗
  • 市場規模及預測：依產品分類
    • 活病毒疫苗
    • 重組疫苗
    • 去活化疫苗
  • 市場規模及預測：依技術分類
    • 蛋製品
    • 重組DNA
    • 細胞衍生的
  • 市場規模及預測：依分銷通路分類
    • 醫院和藥房
    • 政府和機構的供應商
    • 其他
  • 市場規模及預測：依應用領域分類
    • 兒童
    • 青年人
    • 老年人
    • 孕婦
  • 市場規模及預測：依給藥途徑分類
    • 鼻腔
    • 注射
  • 市場規模及預測：以劑型分類
    • 肌肉內注射
    • 鼻內
    • 皮內接種

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • CSL Seqirus
  • Sanofi SA
  • GSK plc
  • AstraZeneca plc
  • BioDiem Ltd
  • FluGen, Inc.
  • Novavax, Inc.
  • Sinovac Biotech Ltd.
  • Viatris
  • KM Biologics Co., Ltd
  • INOVIO Pharmaceuticals
  • EMERGENT
  • Takeda Pharmaceutical Company Limited
  • Vaxart Inc
  • Bharat Biotech
  • Serum Institute of India Pvt. Ltd
  • ABBOTT
  • Zydus Group
  • Pfizer Inc.
  • Moderna, Inc

第9章 關於我們

簡介目錄
Product Code: GIS21920

The global influenza vaccine market is projected to grow from $9.2 billion in 2025 to $16.3 billion by 2035, at a compound annual growth rate (CAGR) of 5.7%. The influenza vaccine market is driven by structured global guidance and strong seasonal demand dynamics. The World Health Organization enables predictable production cycles, while the Centers for Disease Control and Prevention reported 134.6 million doses distributed in the 2025-26 U.S. season. Vaccine effectiveness of around 50% in multiple countries and 26-41% hospitalization reduction in Europe, as per the European Centre for Disease Prevention and Control, support public funding. Global production capacity stands at 1.53 billion doses, though regional disparities persist, with vaccination coverage ranging from below 15% to above 75% across markets.

In the global influenza vaccine market, the product segment is categorized into inactivated, live attenuated, and recombinant vaccines. Inactivated vaccines dominate the segment due to their established safety profile, broad regulatory approvals, and widespread use in national immunization programs, reaching about $8,001.2 million in 2025. These vaccines are widely preferred for mass vaccination and high-risk populations. Meanwhile, live attenuated vaccines are gaining attention for their needle-free administration and ability to stimulate mucosal immunity. Recombinant vaccines are also expanding due to faster, egg-free production and strong immune responses, supporting innovation and improved protection against evolving influenza strains globally.

Market Segmentation
TypeQuadrivalent Vaccines, Trivalent Vaccines
ProductLive Attenuated Vaccine, Recombinant Vaccine, Inactivated Vaccine
TechnologyEgg-based, Recombinant DNA, Cell-based
ApplicationPediatrics, Young Adults, Elderly, Pregnant Women
ModeIntramuscular, Intranasal, Intradermal
Distribution ChannelHospital & Retail Pharmacies, Government & Institutional Suppliers, Others
Route of AdministrationNasal, Injection

In the global influenza vaccine market, the technology segment includes egg-based, cell-based, and recombinant DNA platforms. Egg-based technology remains dominant due to its long-standing production infrastructure and large-scale manufacturing capacity, reaching approximately $6,713.2 million in 2025. However, cell-based vaccines are increasingly adopted for their improved effectiveness and reduced risk of mutations during production. Recombinant DNA technology is also gaining traction due to its precision and independence from egg supply constraints. Continuous updates in strain selection and rising demand for more effective vaccines are driving innovation across all technologies, encouraging manufacturers to enhance production efficiency and vaccine performance.

Geographical Overview

North America leads the global influenza vaccine market in 2025, accounting for approximately 47.6% of total revenue share. Growth is driven by strong immunization programs and continuous regulatory advancements in the United States and Canada. Expanded approvals, such as broader age eligibility and improved vaccine accessibility, are increasing coverage rates. Public health initiatives emphasizing annual vaccination and early distribution strategies further support demand. Additionally, rising awareness of influenza-related hospitalizations and mortality reinforces consistent vaccine uptake, maintaining North America's dominant position in the global market.

The Asia-Pacific region is projected to be the fastest-growing influenza vaccine market, registering a CAGR of 9.6% from 2026 to 2035. This growth is fueled by expanding immunization guidelines and rising disease burden across China, India, Japan, and South Korea. Governments are strengthening vaccination campaigns, updating strain compositions, and promoting broader population coverage. Increasing adoption of quadrivalent vaccines and improved public health outreach are enhancing awareness and accessibility, positioning Asia-Pacific as a high-growth region in the global influenza vaccine market.

Key Trends and Drivers

Rise of Advanced and Digitalized Influenza Vaccination Solutions in the Influenza Vaccine Market:

The Influenza Vaccine Market is witnessing a shift toward advanced, digitally integrated vaccination solutions driven by innovations in mRNA technology, AI-enabled forecasting, and personalized immunization strategies. Companies such as Moderna, Sanofi Pasteur, and Pfizer are advancing quadrivalent vaccines, digital tracking platforms, and AI-guided development. Additionally, Seqirus and GlaxoSmithKline are leveraging predictive analytics and personalized programs to optimize distribution and outcomes. These developments highlight a transition toward precision-driven, connected, and efficient vaccination ecosystems.

Accelerating Development and Delivery of Innovative Influenza Vaccines in the Influenza Vaccine Market:

The Influenza Vaccine Market is driven by rapid advancements in vaccine development, digital surveillance, and distribution optimization. Companies including Pfizer and AstraZeneca are expanding mRNA platforms and real-time monitoring tools to improve pandemic readiness and vaccination coverage. Meanwhile, Seqirus and Sanofi Pasteur are enhancing immune response and logistics through adjuvanted vaccines and scalable packaging. Collaborations by GlaxoSmithKline further support predictive outbreak management. These factors collectively strengthen efficiency, accessibility, and resilience in global immunization systems.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Distribution Channel
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Route of Administration
  • 2.7 Key Market Highlights by Mode

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTLE Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Quadrivalent Vaccines
    • 4.1.2 Trivalent Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Live Attenuated Vaccine
    • 4.2.2 Recombinant Vaccine
    • 4.2.3 Inactivated Vaccine
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Egg-based
    • 4.3.2 Recombinant DNA
    • 4.3.3 Cell-based
  • 4.4 Market Size & Forecast by Distribution Channel (2020-2035)
    • 4.4.1 Hospital & Retail Pharmacies
    • 4.4.2 Government & Institutional Suppliers
    • 4.4.3 Others
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Pediatrics
    • 4.5.2 Young Adults
    • 4.5.3 Elderly
    • 4.5.4 Pregnant Women
  • 4.6 Market Size & Forecast by Route of Administration (2020-2035)
    • 4.6.1 Nasal
    • 4.6.2 Injection
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Intramuscular
    • 4.7.2 Intranasal
    • 4.7.3 Intradermal

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Distribution Channel
      • 5.2.1.5 Application
      • 5.2.1.6 Route of Administration
      • 5.2.1.7 Mode
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Distribution Channel
      • 5.2.2.5 Application
      • 5.2.2.6 Route of Administration
      • 5.2.2.7 Mode
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Distribution Channel
      • 5.2.3.5 Application
      • 5.2.3.6 Route of Administration
      • 5.2.3.7 Mode
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Distribution Channel
      • 5.3.1.5 Application
      • 5.3.1.6 Route of Administration
      • 5.3.1.7 Mode
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Distribution Channel
      • 5.3.2.5 Application
      • 5.3.2.6 Route of Administration
      • 5.3.2.7 Mode
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Distribution Channel
      • 5.3.3.5 Application
      • 5.3.3.6 Route of Administration
      • 5.3.3.7 Mode
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Distribution Channel
      • 5.4.1.5 Application
      • 5.4.1.6 Route of Administration
      • 5.4.1.7 Mode
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Distribution Channel
      • 5.4.2.5 Application
      • 5.4.2.6 Route of Administration
      • 5.4.2.7 Mode
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Distribution Channel
      • 5.4.3.5 Application
      • 5.4.3.6 Route of Administration
      • 5.4.3.7 Mode
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Distribution Channel
      • 5.4.4.5 Application
      • 5.4.4.6 Route of Administration
      • 5.4.4.7 Mode
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Distribution Channel
      • 5.4.5.5 Application
      • 5.4.5.6 Route of Administration
      • 5.4.5.7 Mode
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Distribution Channel
      • 5.4.6.5 Application
      • 5.4.6.6 Route of Administration
      • 5.4.6.7 Mode
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Distribution Channel
      • 5.4.7.5 Application
      • 5.4.7.6 Route of Administration
      • 5.4.7.7 Mode
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Distribution Channel
      • 5.5.1.5 Application
      • 5.5.1.6 Route of Administration
      • 5.5.1.7 Mode
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Distribution Channel
      • 5.5.2.5 Application
      • 5.5.2.6 Route of Administration
      • 5.5.2.7 Mode
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Distribution Channel
      • 5.5.3.5 Application
      • 5.5.3.6 Route of Administration
      • 5.5.3.7 Mode
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Distribution Channel
      • 5.5.4.5 Application
      • 5.5.4.6 Route of Administration
      • 5.5.4.7 Mode
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Distribution Channel
      • 5.5.5.5 Application
      • 5.5.5.6 Route of Administration
      • 5.5.5.7 Mode
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Distribution Channel
      • 5.5.6.5 Application
      • 5.5.6.6 Route of Administration
      • 5.5.6.7 Mode
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Distribution Channel
      • 5.6.1.5 Application
      • 5.6.1.6 Route of Administration
      • 5.6.1.7 Mode
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Distribution Channel
      • 5.6.2.5 Application
      • 5.6.2.6 Route of Administration
      • 5.6.2.7 Mode
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Distribution Channel
      • 5.6.3.5 Application
      • 5.6.3.6 Route of Administration
      • 5.6.3.7 Mode
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Distribution Channel
      • 5.6.4.5 Application
      • 5.6.4.6 Route of Administration
      • 5.6.4.7 Mode
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Distribution Channel
      • 5.6.5.5 Application
      • 5.6.5.6 Route of Administration
      • 5.6.5.7 Mode

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 CSL Seqirus
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Sanofi S.A.
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 GSK plc
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 AstraZeneca plc
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 BioDiem Ltd
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 FluGen, Inc.
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Novavax, Inc.
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Sinovac Biotech Ltd.
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Viatris
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 KM Biologics Co., Ltd
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 INOVIO Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 EMERGENT
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Takeda Pharmaceutical Company Limited
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Vaxart Inc
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bharat Biotech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Serum Institute of India Pvt. Ltd
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 ABBOTT
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Zydus Group
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Pfizer Inc.
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Moderna, Inc
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us